Nocardia infection in organ transplant recipients have not been formally assessed in the current era of transplantation.
common of these include Nocardia asteroides sensu stricto, Nocardia brasiliensis, Nocardia farcinica, Nocardia nova, Nocardia otitidiscaviarum, and Nocardia transvalensis.
In most instances, Nocardia is an opportunistic pathogen, with the majority of infections occurring in immunocompromised hosts, including those with longterm corticosteroid exposure, malignancy, HIV infection, and a history of transplantation [3] . Primary cutaneous infection with N. brasiliensis after a traumatic injury is an exception; the majority of affected individuals are immunocompetent. The frequency of Nocardia species infection in organ transplant recipients is 0.7%-3%, with the majority of infections being described in kidney, heart, and liver transplant recipients [4] [5] [6] [7] . Over time, changes in immunosuppressive regimens (most importantly, the introduction of cyclosporin) have led to a significant reduction in the number of Nocardia infections in heart and kidney transplant recipients [8, 9] . Such changes most likely relate to an improved specificity of immune suppression and a reduction in corticosteroid exposure. The first year after transplantation carries the greatest risk for Nocardia species infection, with several reports indicating a temporal association with episodes of allograft rejection [6, 10, 11] . Cytomegalovirus (CMV) infection, which has immunomodulatory effects [12] , is also thought to be an important cofactor in the development of Nocardia infection [4] , but this has yet to be confirmed in a formal analysis.
Risk factors for Nocardia infection in organ transplantation have not been formally assessed for 25 years [6] , a period in which significant advances have been made in immunosuppressive regimens and antimicrobial prophylactic strategies. Therefore, we performed a study with the following objectives: (1) to systematically assess the risk factors for Nocardia infection in organ transplant recipients during the modern era, using a 1:2 matched case-control study design; and (2) to describe the clinical, radiological, and microbiological characteristics of the largest number of Nocardia infections in organ transplant recipients yet reported from a single institution.
MATERIALS AND METHODS
Study population. The study was conducted at the University of Pittsburgh Medical Center (Pittsburgh, PA), a tertiary care institute specializing in organ transplantation, including liver, kidney, heart, lung, pancreas, intestinal, and multivisceral transplantation. All patients with culture-proven Nocardia infection from January 1995 through December 2005 were included in the analysis. Patients were initially identified from the hospital's microbiology database. This was followed by a detailed review of the patients medical records. Nocardia infection was defined as a positive culture in the presence of clinical and/or radiological features of infection. Disseminated infection was defined as involvement of у2 noncontiguous organs, disease of the CNS, or the presence of Nocardia species in blood samples. The clinical significance of each isolate was determined by 2 transplant infectious diseases physicians blinded to the other's decision. Concordance was obtained for all isolates. Ten of the cases of Nocardia infection have been previously described [13] . The study was approved by the institutional review board of the University of Pittsburgh Medical Center.
For the purposes of risk factor analysis, matched control subjects were obtained from the same institution. Two control subjects were included for each case patient with Nocardia infection. The control subjects were matched for 2 characteristics: (1) transplant type and (2) time of transplantation. The recipients who received transplants immediately before and after the index case patient and who survived at least as long as the time to diagnosis of Nocardia infection in the index case patient were categorized as control subjects.
Clinical data. Data were systematically collected from the hospital's computer-based medical records. For the case patients, the "time of event" was defined as the time of Nocardia infection; for the control subjects, the time of Nocardia infection in the corresponding case patient was used. Variables analyzed for both case patients and control subjects included patient demographic data, transplant type, prior transplantation, presence of diabetes mellitus, renal function at the time of the event, maintenance immunosuppression, an elevated mean calcineurin inhibitor level in the preceding 30 days (115 mg/mL for tacrolimus and 1300 ng/mL for cyclosporin), history of high-dose prednisone therapy in the preceding 6 months (у20 mg of prednisone forу1 month or 12 pulses of 1 g of intravenous methylprednisolone), receipt of a lymphocyte-depleting antibody (alemtuzumab [CD-52 monoclonal antibody], rabbit antithymocyte globulin, muromonab-CD3, or CD-3 monoclonal antibody and rituximab [CD-20 monoclonal antibody]) or lymphocyte-modulating antibody (daclizumab [IL-2 receptor antagonist]) in the preceding 12 months, prophylactic antimicrobials at the time of event, allograft rejection in the preceding 6 months, treatment for allograft rejection, history of CMV infection and/or disease in the preceding 6 months, history of another opportunistic infection in the preceding 3 months, mean lymphocyte and neutrophil counts within 30 days of the event, and mortality at 6 months after the event. All case patients had detailed clinical and microbiological information collected. Two separate investigators reviewed all case patients and control subjects independently.
CMV infection was defined as the detection of viremia by pp65 antigenemia in the absence of symptoms. CMV disease was defined as symptoms and/or signs of an organ-specific illness in conjunction with the detection of CMV in tissue by culture, immunohistochemical analysis, or in situ hybridization [14] . Other opportunistic infections were defined according to current guidelines [14] [15] [16] .
Microbiology. Organisms were initially identified as Nocardia species by the microbiology department at our institution on the basis of their ability to grow aerobically, their colonial and microscopic morphology, and demonstration of partial acid-fast staining. Organisms were then sent to the University of Texas Health Science Center (Tyler, TX) for confirmation and susceptibility testing. From 2003, in vitro susceptibility testing was performed by broth microdilution according to CLSI guidelines [17] . Prior to this, broth microdilution was performed for sulfamethoxazole, and disk diffusion was performed for other antimicrobials.
Statistical analysis. Statistical analyses were performed us- Other opportunistic infection in preceding 3 months 3 (9) 1 (1) , as appropriate. e Defined as 115 mg/mL for tacrolimus and 1300 ng/mL for cyclosporine. All case patients and control subjects were receiving a calcineurin inhibitor at the time of event.
f Alemtuzumab (CD-52 monoclonal antibody), rabbit antithymocyte globulin, muromonab-CD3 or CD-3 monoclonal antibody, and rituximab (CD-20 monoclonal antibody).
ing SAS software, version 8.2 (SAS Institute). Univariate matched ORs were calculated for the potential risk factors for Nocardia infection. Multivariable conditional logistic regression was performed using the SAS procedure PHREG to determine independent risk factors for Nocardia infection. Variables with a P value of !.2 on univariate analysis were included in the multivariable model. Variables were assessed for confounding and collinearity. All P values were 2-tailed, and a value of !.05 was considered to be statistically significant. Of the 27 transplant recipients with pulmonary disease only, 6 (22%) had night sweats, fevers, or constitutional symptoms with no respiratory symptoms. Seven transplant recipients (20%) had disseminated infection, including 4 lung transplant recipients (3 with brain abscesses and 1 with bacteremia and septic arthritis), 1 heart transplant recipient (pulmonary and cutaneous infection), 1 liver transplant recipient (bacteremia), and 1 intestinal transplant recipient (bacteremia and prostatitis) [18] .
RESULTS

Epidemiology. A total of 35
Coexisting infections and temporal relationship to allograft rejection. Seven recipients (20%) had a coexisting infection ( [3%] ). The final 2 case patients were treated with ceftriaxone, imipenem or meropenem, and minocycline. All case patients except 1 received empirical treatment with an antibiotic that was active against the corresponding isolate. A lung recipient with N. asteroides infection was treated with empirical imipenem (to which the infecting strain had intermediate susceptibility) and oral TMP-SMZ (to which the infecting strain was resistant). Despite this, the patient recovered well, and when susceptibility results were available, therapy was changed to doxycyline and gatifloxacin.
Among the 29 case patients who received definitive therapy Outcome. Thirty-one case patients (89%) experienced cure of Nocardia infection, including 6 of 7 case patients with disseminated disease. Five case patients (14%) died during therapy. In 4 of these cases, death was at least partly attributable to Nocardia infection: 2 of the patients who died were lung transplant recipients (1 of whom had pulmonary infection due to N. farcinica and 1 of whom had multiple brain abscesses due to N. nova), 1 was a heart transplant recipient with pulmonary infection due to N. nova, and 1 was a multivisceral transplant recipient with pulmonary infection due to N. asteroides. Compared with 70 matched control subjects, recipients with Nocardia infection had a significantly greater 6-month mortality rate (5 [14%] of 35 patients with Nocardia infection died, compared with 1 [4%] of 70 matched control subjects;
). P p .015
DISCUSSION
The frequency of Nocardia infection in organ transplant recipients at our institution was 0.6%, a figure that is consistent with recently published literature [4, 19] . The highest frequency was in lung transplant recipients, followed by heart, small bowel, kidney, and liver transplant recipients. Such data conflict with data reported previously, in which kidney, heart, and liver transplant recipients have had the highest rates of Nocardia infection [20] [21] [22] . Two key points may explain these epidemiological differences. First, transplant centers are now performing transplantation of a greater breadth of organ types. Also, the absolute number of transplantations is increasing, especially for relatively newer organ types, such as lungs and intestines. Lung transplantation has only emerged in the past [23] . Second, much of the literature regarding the susceptibility of organ transplant recipients to Nocardia infection predates the expansion of these newer transplant types [20] , and such studies are most often derived from single-organ transplantation programs [5] [6] [7] . In the present study, we evaluated, to the best of our knowledge, the broadest range of transplant types reported in the literature to date, and we provide an update on the frequency of Nocardia infection in the modern era of transplantation.
To our knowledge, there has only been 1 other matched casecontrol study published in the literature that assesses the risk factors for Nocardia infection in organ transplant recipients [6] . This study, published over 25 years ago, involved 21 cardiac transplant recipients with Nocardia infection from a single institution. These patients were compared with all other cardiac transplant recipients without Nocardia infection, as well as a time-matched cohort (1:1 ratio). No risk factors were identified in this analysis [6] . Risk factors for Nocardia infection in kidney transplant recipients have repeatedly been described in previous reviews [3, 7, 21] , although significant limitations exist with the data. Many of the referenced studies were designed to assess overall infection risk among kidney transplant recipients, rather than risk of Nocardia infection alone [24, 25] . One study reported the infectious etiologies causing death in kidney transplant recipients, with only 2 case patients with Nocardia infection included [26] . A further study identified that multiple early-rejection episodes were a risk factor for fungal and nocardial infections [10] , although only 4 case patients with Nocardia infection were included. Finally, such studies are over 28 years old and, given the changes in prophylactic and immunosuppressant regimens used in transplantation, a reevaluation of the frequency, risk factors, and outcomes of Nocardia infection was necessary.
After performing a matched case-control study (1:2 ratio), we determined that high-dose prednisone and a history of CMV disease in the preceding 6 months and an elevated mean calcineurin inhibitor level in the preceding 30 days were independent risk factors for Nocardia infection in organ transplant recipients. Such variables have clear biological plausibility. Prednisone is a broadly acting immunosuppressant, affecting both the innate and adaptive immune responses, and has previously been associated with the development of Nocardia infection [2, 7, 20] . The immunomodulatory effects of CMV are increasingly being recognized [12] , with previous reports associating it with other viral, bacterial, fungal, and protozoan infections [27] [28] [29] . To our knowledge, its role as a risk factor for Nocardia infection has not been formally assessed, and our data further support the importance of aggressive management of CMV disease in preventing the "indirect" effects of CMV infection. The calcineurin inhibitors, cyclosporin and tacrolimus, inhibit T cell activation by binding to cyclophilin and FK-binding protein 12, respectively [30] . T cells are essential for an adequate host response against Nocardia infection, primarily through the activation of macrophages and the stimulation of a cellular immune response [20] . Allograft rejection has often been thought of as a predisposing variable for Nocardia infection in organ transplant recipients [6, 10, 11] , but confounding variables, such as augmented immunosuppression, are often not accounted for. Our data illustrate the importance of this, whereby allograft rejection was a highly significant risk factor on univariate analysis ( ), but, after P ! .001 adjusting for confounders in the multivariable model, it was no longer significant.
At our institution, all organ transplant recipients are prescribed TMP-SMZ for Pneumocystis jirovecii pneumonia prophylaxis, most commonly at a dosage of 1 single-strength tablet 3 times per week. Twenty-four (69%) of the 35 transplant recipients with Nocardia infection were receiving prophylactic doses of TMP-SMZ at the time of their infection. All breakthrough Nocardia isolates (except 1) were susceptible to this agent. After analyzing this variable using matched control subjects, TMP-SMZ prophylaxis was not shown to be protective against Nocardia infection. Breakthrough nocardial infections that occur while patients are receiving TMP-SMZ have previously been reported in both solid-organ [8] and bone marrow transplant recipients [31] . In patients with HIV infection, use of TMP-SMZ as P. jirovecii pneumonia prophylaxis has often been postulated as a reason for the low incidence of Nocardia infection [21] . However, the dose administered in this population has traditionally been higher than the dose administered to our organ transplant recipients [32] . These data indicate that the use of TMP-SMZ in low dosages for P. jirovecii pneumonia prophylaxis is unreliable in preventing Nocardia infection in organ transplant recipients, despite favorable susceptibility results.
Despite the absence of randomized, controlled trials investigating the treatment of Nocardia infection, combination therapy is frequently used. The reasons for this include the diversity of species and their susceptibility nuances, the prolonged period before susceptibility results are known (if susceptibility testing is performed at all), and the severity of illness, especially in cases of disseminated disease. The ideal choice of agents is less established. The most common drug regimen for empirical therapy in our cohort was therapy with TMP-SMZ, ceftriaxone, and imipenem. Such a combination had excellent activity against all isolates. Murine models of CNS and pulmonary nocardiosis have indicated that the combination of amikacin and imipenem is most effective [33, 34] . Unfortunately, aminoglycoside use in organ transplant recipients is greatly limited by the high rate of preexisting renal dysfunction (49% in our study). Linezolid, the first agent in the class of oxazolidinones, has shown excellent in vitro activity against all of the clinically relevant species of Nocardia [35] . Clinical success has also been reported [36] . Unfortunately, bone marrow and other toxicities, which were seen in one-half of our patients, limit the use of linezolid for prolonged therapy. However, its role as initial therapy for the stabilization of severely unwell, immunocompromised patients with disseminated disease is attractive.
In conclusion, we have formally assessed the risk factors for Nocardia infection in the current era of organ transplantation, showing that high-dose steroids, CMV disease, and high levels of calcineurin inhibitors are independent risk factors. The deficiencies of low dose TMP-SMZ, as used for P. jirovecii pneumonia prophylaxis, for the prevention of Nocardia infection are well illustrated. Given the rapidly increasing population of immunocompromised patients, Nocardia infection is likely to continue to be an important opportunistic disease.
